Abalos was founded to translate an innovative immuno-virotherapy approach into novel anti-cancer therapies
Dr. Marcus Kostka
CEO
Dr. Marcus Kostka
CEO
Location: Germany, North Rhine-Westphalia, Dusseldorf
Total raised: $63.16M
Investors 3
| Date | Name | Website |
| - | Coparion | coparion.v... |
| - | Gründerfon... | gruenderfo... |
| - | High-Tech ... | htgf.de |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.10.2021 | Series A | $49.92M | - |
| 15.10.2019 | Series A | $13.24M | - |
Mentions in press and media 6
| Date | Title | Description |
| 15.10.2021 | Abalos Therapeutics Raises €32.5M in Series A Extension | Abalos Therapeutics, a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in Series A extension round. This additional round, which brings the total raise... |
| 14.10.2021 | Abalos Therapeutics : Completes Series A Extension Bringing Total Raised to EUR 43 Million | Abalos Therapeutics announced today an extension to its Series A funding round bringing the total raised in this round to EUR 43 million (USD 50 million). The extension was led by Seventure Partners with support from Coparion, Ventura BioMe... |
| 14.10.2021 | Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million | Additional EUR 32.5 million will support clinical readiness and accelerate lead immuno-virotherapy candidates toward clinical proof-of-concept. |
| 15.10.2019 | Abalos Therapeutics Raises €12M in Series A Funding | Abalos Therapeutics, an Essen, Germany-based developer of novel immuno-virotherapies against cancer, raised €12m in Series A financing. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and Gruenderfonds Ruhr, with participat... |
| - | Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer | Abalos Therapeutics announced today a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that pref... |
| - | Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million | October 14, 2021 |